tildrakizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5281 1326244-10-3

Description:

MoleculeDescription

Molfile

Synonyms:

  • tildrakizumab
  • ilumya
  • tildrakizumab-asmn
  • MK-3222
  • SCH-900222
  • SUNPG 1622
  • SUNPG 1623
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
1.11 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 17, 2018 EMA ALMIRALL SA
March 20, 2018 FDA SUN PHARMA GLOBAL
June 29, 2020 PMDA Sun Pharma Japan Ltd.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 55.69 53.75 19 113 247518 79496738

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC17 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000192798 Interleukin-23 Antagonists
FDA EPC N0000192799 Interleukin-23 Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Plaque psoriasis indication 200965009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-23 Cytokine ANTIBODY BINDING Kd 9.50 IUPHAR DRUG LABEL

External reference:

IDSource
DEW6X41BEK UNII
C4043954 UMLSCUI
CHEMBL2108681 ChEMBL_ID
DB14004 DRUGBANK_ID
D10400 KEGG_DRUG
9672 INN_ID
8093 IUPHAR_LIGAND_ID
277523 MMSL
34167 MMSL
d08783 MMSL
017483 NDDF
771591006 SNOMEDCT_US
771665003 SNOMEDCT_US
4037782 VANDF
4037783 VANDF
2053436 RXNORM
C000598434 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ILUMYA HUMAN PRESCRIPTION DRUG LABEL 1 47335-177 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 26 sections
ILUMYA HUMAN PRESCRIPTION DRUG LABEL 1 47335-177 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 26 sections
ILUMYA HUMAN PRESCRIPTION DRUG LABEL 1 47335-177 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 26 sections